Navigation Links
Effectene Transfection Reagent provides efficient gene delivery ,,, to primary neuronal cell cultures

Jochen Meier, Ivonne Strmel, Radu Iosub, Sonja Schmidt, and Rosemarie Grantyn
Developmental Physiology, Johannes Mller Institute, Humboldt University Medical School (Charit), Berlin, Germany

Efficient delivery of DNA to primary neuronal cell cultures is of critical importance for extending our knowledge of the molecular basis of neuronal physiology. Here, we describe the use of Effectene Transfection Reagent for successful transfection of primary differentiated neurons in rat superior colliculus cultures.

Enhanced green fluorescent protein (EGFP) chimeras have proven to be a powerful tool for studying the underlying cellular mechanisms for dynamic remodeling of synaptic compounds in living neurons (1). However, a major obstacle to the use of such chimeras is an effective gene delivery method. Gene delivery based on non-viral DNA vehicles is an attractive alternative because it can be applied under a wide range of laboratory conditions. We developed a transfection procedure using Effectene Reagent and found it highly suited for easy and efficient transfection of differentiated neurons in primary cultures from rat superior colliculus. Effectene Reagent shows low cytotoxicity and delivers efficient transfection using small amounts of DNA. Furthermore, transfection can be carried out in the presence of serum.

Materials and methods

Superior colliculus neurons were prepared from embryonic day 19 Wistar rats, and cells were plated at a density of 7.5 x 104 cells/cm2 on laminin-coated glass coverslips (16 mm). Cultures were maintained in neurobasal B27 medium supplemented with 1% fetal calf serum. After neuron attachment, coversli
'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Effectene Transfection Reagent
2. Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell Line
3. Optimizing Transfection Conditions for Studying Signal Transduction Pathways
4. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
5. Improve Lipid- or Calcium Phosphate-Mediated Transfection of Human Dermal Fibroblasts
6. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
7. Low-Toxicity, Lipid-Mediated Transfection of Mammalian Cells
8. Mycoplasma Contamination Reduces the Effect of Lipid-Mediated Transfection of Mammalian Cells
9. High-Efficiency Transfections Achieved with New Low-Toxicity Reagent
10. Efficient Transfection of Neurospora Crassa
11. Eppendorf Multiporator Transfection Protocols for Eukaryotic Cells

Post Your Comments:
(Date:11/9/2009)..., SAN DIEGO, Nov. 9 NexBio, Inc....9 annual American College of Allergy, Asthma, and ...s entitled "DAS181 (Fludase®), a Sialidase, D...lammatory Effects in Animal Models of Asthma". ,...broad spectrum host-targeting drug candidate being...
(Date:11/9/2009)... Product release is a resea...ubjects, research facilities and research safety s...n. , Cedar Knolls, NJ (PR...nounced today that it has unveiled Pristima™...r research facilities that track the use and care ...
(Date:11/8/2009)...,, MOUNTAIN VIEW, Calif. Nov. 5, 2009 Comple...ncing company, today announced publication of a re...ietary DNA sequencing platform, including analysis...s. The consumables cost for these three genomes se...arrays ranged from $8,005 for 87x coverage to $1,7...
(Date:11/6/2009)..., LYNBROOK, N.Y., Nov. 6 /PRNewswire-FirstCall/ ...), a biopharmaceutical company developing first-in... its financial results for the third quarter ended...py that, in September of this year, the FDA,s Arth...by a vote of 12-0, the approval of XIAFLEX(TM) for...
Breaking Biology Technology:NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 2NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009 3Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6
...auna Kea Technologies and VisualSonics today annou...ion agreement through which VisualSonics will mark...imaging systems to pre-clinical researchers on a w...rs with a new way to understand physiological phen...itu in animal subjects. For the first time, pre-cl...
...Nasdaq: IDMI ) today reported financial results ...r 31, 2008. Financial information presented repre... and its subsidiary, IDM Pharma S.A. , , Total re... $0.3 million, and net loss was $1.8 million or $0... the year ended December 31, 2008 were $3.1 millio...
...SHP,NASDAQ: SHPGY ), the global specialty biopha...n agreement with GlaxoSmithKline plc (NYSE: GSK ...sules CII with the aim of,improving recognition an...eement covers the United States and will more than...es effort for VYVANSE by adding over 600 sales,rep...
Other Biology Technology:VisualSonics to Sell Mauna Kea Technologies' Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market 2VisualSonics to Sell Mauna Kea Technologies' Cellvizio(R) LAB on a Worldwide Basis to Animal Imaging Market 3IDM Pharma Reports 2008 Financial Results 2IDM Pharma Reports 2008 Financial Results 3IDM Pharma Reports 2008 Financial Results 4IDM Pharma Reports 2008 Financial Results 5IDM Pharma Reports 2008 Financial Results 6IDM Pharma Reports 2008 Financial Results 7IDM Pharma Reports 2008 Financial Results 8Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6
(Date:11/4/2009)...tural science) , United States Using Less Wate...ay than it did 35 years ago, despite a 30 percent ...tly attributable to alternative cooling methods at...s. According to the latest USGS water use report, ... goes to cooling thermoelectric power plants. Irri...
(Date:11/4/2009)...teria, it turns out, hold the power to help milita... world clean up toxic waste on test sites. , Com... invented back in World War II and have been used ...rgy compounds are often used to propel tank shells... But with increased knowledge of their environmen...
(Date:11/4/2009)...., Oct. 19 Spectros, developer and...aging devices which shed light on life-threatening...usive distribution deals for both its T-Stat®...ered include Australia, New Zealand, The Netherla...y, France, Spain, Portugal, Poland, Greece, Turkey...
Breaking Biology News(10 mins):USGS science picks 2USGS science picks 3USGS science picks 4USGS science picks 5USGS science picks 6USGS science picks 7Genomic research will enable greener cleanup of military explosive test sites 2Spectros Signs New International Distribution Deals 2VIVUS Announces Promotion of Peter Tam to President 5941 1VIVUS Announces Promotion of Peter Tam to President 5941 2VIVUS Announces Promotion of Peter Tam to President 5941 3MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 1MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 2MarketsandMarkets 3A Global Stem Cell and Advanced Technologies Market Worth US 24 88 3 Billion By 2014 14699 3Hearing Planet Publishes Hearing Aid Buyers 26apos 3B Guide 60589 1Hearing Planet Publishes Hearing Aid Buyers 26apos 3B Guide 60589 2
...the University of Michigan Medical School have dis...arly-onset form of kidney disease and renal failur...d phospholipase C epsilon or PLCE1. , Identifying ... PLCE1 affects the development of podocytes ?speci...s ability to remove waste products from blood, whi...
... the Université de Montréal has concluded that peo...r a night of studying will strongly hurt their rec...he current issue of Neuropsychopharmacology was co...f Psychology at the Université de Montréal. Dr. Ca...ital du Sacré-Coeur de Montréal. , "We already kn...
...al studies of the interactions between oscillating...the toughest questions in ecology, including the n...ing to an article in the December 2006 issue of Bi...niversity of Michigan, shows how extensions of est... populations oscillate in synchrony because of int...
Other Biology News:Mutant gene causes severe kidney disease in infants 2Mutant gene causes severe kidney disease in infants 3Mutant gene causes severe kidney disease in infants 4Negative effects of caffeine are stronger on daytime sleep than on nocturnal sleep 2
Expansion and Cryopreservation of Cells from Meridian Life Science, Inc.
HandyStep manual repeating pipette from BrandTech Scientific
Zymo-Spin I-96 from Zymo Research
RT-PCR Grade Water from Ambion
Biology Products: